Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:07:06.022Z.
Calculation as of: 2026-10-06T17:07:06.022Z.
Quote observation: 2026-10-06T17:05:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.47B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49B
EBITDA Yield
11.25%
TTM Avg
9.08%
3Y Avg
8.50%
5Y Avg
9.04%
Market Cap
$1.46B
EBITDA Yield
11.13%
TTM Avg
6.15%
3Y Avg
7.10%
5Y Avg
6.61%
Market Cap
$1.50B
EBITDA Yield
1.39%
TTM Avg
0.46%
3Y Avg
1.07%
5Y Avg
1.02%
Market Cap
$1.44B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
EBITDA Yield
N/A
TTM Avg
19.73%
3Y Avg
19.73%
5Y Avg
19.73%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.48B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.45B | 3.78% | 6.63% | 3.69% | 3.19% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 11.25% | 9.08% | 8.50% | 9.04% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 11.13% | 6.15% | 7.10% | 6.61% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 1.39% | 0.46% | 1.07% | 1.02% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | N/A | 19.73% | 19.73% | 19.73% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 8.75% | 3.11% | 3.11% | 3.25% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
